BSE: 543828 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sudarshan Pharma Industries Ltd is a average quality company.
The key valuation ratios of Sudarshan Pharma Industries Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sudarshan Pharma Industries Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 16% | 12.2% | 16% | 19.5% | 12% | 14.6% | 18.7% | 15.3% | 13.7% | - |
| Value Creation Index ⓘ | 0.1 | -0.1 | 0.1 | 0.4 | -0.1 | 0.1 | 0.3 | 0.1 | 0.0 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||||||||
| Sales ⓘ | 37.9 | 55.4 | 88.2 | 139 | 148 | 193 | 357 | 461 | 466 | 466 |
| Sales YoY Gr. | - | 46.1% | 59.2% | 57.8% | 6.4% | 30.7% | 84.7% | 29.2% | 0.9% | - |
| Adj EPS ⓘ | 0.3 | 0 | 0.1 | 0.3 | 0.1 | 0.3 | 0.6 | 0.3 | 0.5 | 0.5 |
| YoY Gr. | - | -88.2% | 125% | 177.8% | -44% | 92.9% | 103.7% | -45.5% | 56.7% | - |
| BVPS (₹) ⓘ | 0.6 | 0.9 | 1.1 | 2 | 2.1 | 2.4 | 3.1 | 4.2 | 4.6 | 4.6 |
| Adj Net Profit ⓘ | 0.1 | 0.2 | 0.7 | 2.3 | 1.3 | 2.6 | 5.3 | 7.2 | 11.2 | 11 |
| Cash Flow from Ops. ⓘ | 1.8 | -1.6 | 0 | -1 | 0.5 | 2.7 | -3.7 | -28.8 | 8 | - |
| Debt/CF from Ops. ⓘ | 1.2 | -3.6 | -1286.2 | -14.3 | 40.4 | 11.1 | -8.3 | -1.2 | 13.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 27.3% | 34% | 0.9% | ||||
| Adj EPS ⓘ | NA | 13.5% | 20.3% | 56.7% | ||||
| BVPSⓘ | NA | 18.8% | 25.3% | 10.5% | ||||
| Share Price | - | - | - | 418% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 56.1 | 9.3 | 12.6 | 17.2 | 6.9 | 12.3 | 20.3 | 11 | 10.6 | 10.1 |
| Op. Profit Mgn % ⓘ | 0.9 | 1.1 | 0.8 | 3.1 | 3.3 | 3.7 | 3.1 | 3.2 | 4.9 | NAN |
| Net Profit Mgn % ⓘ | 0.2 | 0.3 | 0.8 | 1.7 | 0.9 | 1.3 | 1.5 | 1.6 | 2.4 | 2.4 |
| Debt to Equity ⓘ | 12.9 | 1.8 | 1.2 | 0.8 | 1.1 | 1.3 | 1 | 0.3 | 1 | - |
| Working Cap Days ⓘ | 0 | 88 | 102 | 96 | 116 | 135 | 113 | 126 | 170 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 28 | 40 | 42 | 61 | 65 | 46 | 45 | 82 | 0 |
Sales growth is growing at healthy rate in last 3 years 34.03%
Net Profit is growing at healthy rate in last 3 years 20.29%
Debt to equity has declined versus last 3 years average to 0.96
Return on Equity has declined versus last 3 years average to 10.10%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.5 | 0.5 |
| TTM Sales (₹ Cr.) | 466 | 464 |
| BVPS (₹.) ⓘ | 4.6 | 4.6 |
| Reserves (₹ Cr.) ⓘ | 88 | 88 |
| P/BV ⓘ | 8.71 | 8.70 |
| PE ⓘ | 85.62 | 84.88 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 5.82 / 46.00 |
| All Time Low / High (₹) | 5.18 / 46.00 |
| Market Cap (₹ Cr.) | 972 |
| Equity (₹ Cr.) | 24.1 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 38 | 55 | 88 | 139 | 148 | 193 | 357 | 461 | 466 |
| Operating Expenses ⓘ | 38 | 55 | 87 | 135 | 143 | 186 | 346 | 447 | 443 |
| Manufacturing Costs | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 5 | 4 |
| Material Costs | 36 | 53 | 83 | 129 | 137 | 178 | 335 | 431 | 425 |
| Employee Cost | 0 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 3 |
| Other Costs ⓘ | 1 | 1 | 2 | 2 | 4 | 6 | 7 | 9 | 12 |
| Operating Profit ⓘ | 0 | 1 | 1 | 4 | 5 | 7 | 11 | 15 | 23 |
| Operating Profit Margin (%) | 0.9% | 1.1% | 0.8% | 3.1% | 3.2% | 3.7% | 3.1% | 3.2% | 4.9% |
| Other Income ⓘ | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 3 |
| Interest ⓘ | 0 | 0 | 1 | 2 | 3 | 3 | 3 | 5 | 9 |
| Depreciation ⓘ | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0 | 0 | 1 | 3 | 2 | 4 | 7 | 9 | 15 |
| Tax ⓘ | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 4 |
| Profit After Tax | 0 | 0 | 1 | 2 | 1 | 3 | 5 | 7 | 11 |
| PAT Margin (%) | 0.2% | 0.3% | 0.8% | 1.7% | 0.9% | 1.4% | 1.5% | 1.5% | 2.4% |
| Adjusted EPS (₹) | 0.3 | 0.0 | 0.1 | 0.3 | 0.1 | 0.3 | 0.5 | 0.3 | 0.5 |
| Dividend Payout Ratio (%) | 0% | 96% | 0% | 0% | 0% | 0% | 0% | 10% | 0% |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 0 | 3 | 9 | 19 | 20 | 23 | 30 | 101 | 112 | |
| Share Capital ⓘ | 0 | 2 | 5 | 10 | 10 | 10 | 10 | 24 | 24 | |
| Reserves ⓘ | 0 | 1 | 4 | 9 | 10 | 13 | 20 | 77 | 88 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt | 2 | 6 | 10 | 14 | 21 | 30 | 29 | 31 | 103 | |
| Long Term Debt | 1 | 2 | 3 | 4 | 7 | 8 | 5 | 13 | 10 | |
| Short Term Debt | 1 | 3 | 8 | 10 | 14 | 21 | 24 | 18 | 93 | |
| Trade Payables | 6 | 11 | 12 | 16 | 15 | 44 | 74 | 92 | 57 | |
| Others Liabilities ⓘ | 0 | 0 | 1 | 1 | 2 | 3 | 5 | 8 | 14 | |
| Total Liabilities ⓘ | 8 | 20 | 31 | 50 | 58 | 99 | 138 | 232 | 285 | |
Fixed Assets | ||||||||||
| Gross Block | 0 | 0 | 0 | 2 | 6 | 8 | 8 | 22 | 24 | |
| Accumulated Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 4 | |
| Net Fixed Assetsⓘ | 0 | 0 | 0 | 2 | 6 | 6 | 6 | 20 | 21 | |
| CWIP ⓘ | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 2 | |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 17 | |
| Inventories | 1 | 3 | 7 | 10 | 17 | 24 | 47 | 75 | 84 | |
| Trade Receivables | 7 | 14 | 17 | 26 | 27 | 60 | 73 | 82 | 123 | |
| Cash Equivalents | 0 | 1 | 0 | 4 | 1 | 1 | 0 | 12 | 0 | |
| Others Assetsⓘ | 0 | 2 | 7 | 7 | 7 | 7 | 10 | 32 | 38 | |
| Total Assets ⓘ | 8 | 20 | 31 | 50 | 58 | 99 | 138 | 232 | 285 | |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 2 | -2 | 0 | -1 | 1 | 3 | -4 | -29 | 8 |
| PBT ⓘ | 0 | 0 | 1 | 3 | 2 | 4 | 7 | 9 | 15 |
| Adjustment ⓘ | 0 | 0 | 1 | 2 | 3 | 4 | 4 | 6 | 9 |
| Changes in Working Capital ⓘ | 1 | -2 | -2 | -5 | -4 | -4 | -13 | -42 | -14 |
| Tax Paid ⓘ | 0 | 0 | 0 | -1 | 0 | -1 | -2 | -2 | -2 |
| Cash Flow From Investing Activity ⓘ | 0 | 0 | 0 | -3 | -3 | -1 | -2 | -26 | -7 |
| Capex | 0 | 0 | 0 | -3 | -4 | -1 | -1 | -14 | -2 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12 | -4 |
| Others ⓘ | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | -1 |
| Cash Flow From Financing Activityⓘ | -2 | 2 | -1 | 8 | 0 | -1 | 4 | 66 | -12 |
| Net Proceeds from Shares ⓘ | 0 | 3 | 5 | 8 | 0 | 0 | 2 | 64 | 0 |
| Net Proceeds from Borrowing ⓘ | -1 | 0 | -4 | 2 | 3 | 1 | 6 | 8 | -2 |
| Interest Paid ⓘ | 0 | 0 | -1 | -2 | -3 | -3 | -3 | -5 | -9 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
| Net Cash Flow ⓘ | 0 | 0 | -1 | 3 | -2 | 0 | -1 | 11 | -12 |
| PARTICULARS | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | N/A | 9.26 | 12.59 | 17.21 | 6.61 | 12.62 | 20.09 | 10.77 | 10.68 | |
| ROCE (%) | N/A | 12.15 | 15.98 | 19.49 | 12.02 | 14.64 | 18.68 | 15.25 | 13.65 | |
| Asset Turnover Ratio | 4.58 | 3.93 | 3.46 | 3.43 | 2.73 | 2.46 | 3.02 | 2.49 | 1.8 | |
| PAT to CFO Conversion(x) | N/A | N/A | 0 | -0.5 | 1 | 1 | -0.8 | -4.14 | 0.73 | Working Capital Days |
| Receivable Days | 63 | 67 | 64 | 57 | 65 | 82 | 68 | 61 | 80 | |
| Inventory Days | 10 | 15 | 21 | 22 | 34 | 39 | 36 | 48 | 62 | |
| Payable Days | 60 | 58 | 49 | 39 | 41 | 61 | 64 | 70 | 64 | |
Sudarshan Pharma Industries was originally incorporated on July 23, 2008 as a Private Limited Company as “Sudarshan Speciality Chemsolve Private Limited” under the provisions of the Companies Act, 1956 with the Registrar of Companies, Mumbai. Later in the year 2016, the name of the company was changed from “Sudarshan Specialty Chemsolve Private Limited” to “Sudarshan Pharma Industries Private Limited” under the Companies Act, 2013 pursuant to a special resolution passed by its shareholders at the EGM held on November 25, 2016 and vide certificate of incorporation dated December 17, 2016 issued by the Registrar of Companies, Mumbai. Subsequently, pursuant to a Special Resolution of its Shareholders passed in the Extra-Ordinary General Meeting held on December 12, 2016 the company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the company was changed to ‘Sudarshan Pharma Industries Limited’ and a Fresh Certificate of Incorporation consequent to Conversion was issued on January 05, 2017 by the Registrar of Companies, Mumbai.
The company is engaged in the business of manufacturing and trading of specialty chemicals & intermediates for pharma, agro chemicals, coating, paints, adhesive and various other industries. It is also into Active Pharmaceuticals Ingredients manufacturing. Some products it outsources and manufactures at its toll manufacturing facility, it is also into specialty chemicals imports & exports as well as supply of same to the actual users. As per the clients need and requirements, it provides customize specialty chemicals to its clients in India and abroad regularly. Its Specialty chemicals & its Intermediates have wide application in sectors like pharma, agro chemicals, performance chemicals, resins, paint, food, adhesive and various other Industries.
It is also involved in contract manufacturing, outsource & supply of generic pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals. It carries about Ethical marketing of pharmaceutical formulation & products in the Domestic and International market through its own distribution network and Sales force under its own brands. The company & its executives have developed the skill and expertise in innovation in specialty chemical, bulk drugs, API and pharmaceutical formulation to provide the products having wide application in pharma, agro chemicals, performance chemicals, resins, paint, food, adhesive and various other Industries. It offers services of QC and Formulation Development to provide customised solutions to its customers and assists them in sourcing the innovative products as per their needs.
Business area of the company
The company is engaged in the business of manufacturing and trading of Specialty Chemicals, Intermediates & Active Pharmaceuticals Ingredients.
Products and services of the company
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
